CN112225805A - 纳米抗体及其应用 - Google Patents
纳米抗体及其应用 Download PDFInfo
- Publication number
- CN112225805A CN112225805A CN202011125794.6A CN202011125794A CN112225805A CN 112225805 A CN112225805 A CN 112225805A CN 202011125794 A CN202011125794 A CN 202011125794A CN 112225805 A CN112225805 A CN 112225805A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid sequence
- nanobody
- gly
- rsv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010003723 Single-Domain Antibodies Proteins 0.000 title claims description 29
- 239000003814 drug Substances 0.000 claims abstract description 17
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 88
- 239000000539 dimer Substances 0.000 claims description 31
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 14
- 239000003153 chemical reaction reagent Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 239000013604 expression vector Substances 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000002773 nucleotide Substances 0.000 claims description 6
- 125000003729 nucleotide group Chemical group 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 238000009007 Diagnostic Kit Methods 0.000 claims description 3
- 239000012752 auxiliary agent Substances 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 230000008878 coupling Effects 0.000 claims description 2
- 238000010168 coupling process Methods 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 abstract description 36
- 108090000623 proteins and genes Proteins 0.000 abstract description 32
- 239000000427 antigen Substances 0.000 abstract description 23
- 102000036639 antigens Human genes 0.000 abstract description 23
- 108091007433 antigens Proteins 0.000 abstract description 23
- 102000004169 proteins and genes Human genes 0.000 abstract description 18
- 230000027455 binding Effects 0.000 abstract description 13
- 230000003472 neutralizing effect Effects 0.000 abstract description 12
- 238000001514 detection method Methods 0.000 abstract description 11
- 108091026890 Coding region Proteins 0.000 abstract description 10
- 238000003745 diagnosis Methods 0.000 abstract description 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 241000725643 Respiratory syncytial virus Species 0.000 description 74
- 108010086434 alanyl-seryl-glycine Proteins 0.000 description 26
- 210000004027 cell Anatomy 0.000 description 25
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 description 17
- XKUKSGPZAADMRA-UHFFFAOYSA-N glycyl-glycyl-glycine Natural products NCC(=O)NCC(=O)NCC(O)=O XKUKSGPZAADMRA-UHFFFAOYSA-N 0.000 description 16
- OYTPNWYZORARHL-XHNCKOQMSA-N Gln-Ala-Pro Chemical compound C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCC(=O)N)N OYTPNWYZORARHL-XHNCKOQMSA-N 0.000 description 13
- PMGDADKJMCOXHX-UHFFFAOYSA-N L-Arginyl-L-glutamin-acetat Natural products NC(=N)NCCCC(N)C(=O)NC(CCC(N)=O)C(O)=O PMGDADKJMCOXHX-UHFFFAOYSA-N 0.000 description 13
- WGNOPSQMIQERPK-UHFFFAOYSA-N Leu-Asn-Pro Natural products CC(C)CC(N)C(=O)NC(CC(=O)N)C(=O)N1CCCC1C(=O)O WGNOPSQMIQERPK-UHFFFAOYSA-N 0.000 description 13
- UIDJDMVRDUANDL-BVSLBCMMSA-N Trp-Tyr-Arg Chemical compound [H]N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O UIDJDMVRDUANDL-BVSLBCMMSA-N 0.000 description 13
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 13
- 108010008355 arginyl-glutamine Proteins 0.000 description 13
- 108010078144 glutaminyl-glycine Proteins 0.000 description 13
- 108010026364 glycyl-glycyl-leucine Proteins 0.000 description 13
- 108010020755 prolyl-glycyl-glycine Proteins 0.000 description 13
- OEVCHROQUIVQFZ-YTLHQDLWSA-N Ala-Thr-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@@H](C)C(O)=O OEVCHROQUIVQFZ-YTLHQDLWSA-N 0.000 description 12
- ZMUQQMGITUJQTI-CIUDSAMLSA-N Asn-Leu-Asn Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O ZMUQQMGITUJQTI-CIUDSAMLSA-N 0.000 description 12
- MSHXWFKYXJTLEZ-CIUDSAMLSA-N Gln-Met-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCC(=O)N)N MSHXWFKYXJTLEZ-CIUDSAMLSA-N 0.000 description 12
- ZVXMEWXHFBYJPI-LSJOCFKGSA-N Gly-Val-Ile Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O ZVXMEWXHFBYJPI-LSJOCFKGSA-N 0.000 description 12
- MGDFPGCFVJFITQ-CIUDSAMLSA-N Pro-Glu-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O MGDFPGCFVJFITQ-CIUDSAMLSA-N 0.000 description 12
- YQQKYAZABFEYAF-FXQIFTODSA-N Ser-Glu-Gln Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQQKYAZABFEYAF-FXQIFTODSA-N 0.000 description 12
- VGNLMPBYWWNQFS-ZEILLAHLSA-N Thr-Thr-His Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N)O VGNLMPBYWWNQFS-ZEILLAHLSA-N 0.000 description 12
- 108010036413 histidylglycine Proteins 0.000 description 12
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 12
- PQWTZSNVWSOFFK-FXQIFTODSA-N Arg-Asp-Asn Chemical compound C(C[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)N)C(=O)O)N)CN=C(N)N PQWTZSNVWSOFFK-FXQIFTODSA-N 0.000 description 11
- KRRMJKMGWWXWDW-STQMWFEESA-N Gly-Arg-Phe Chemical compound NC(=N)NCCC[C@H](NC(=O)CN)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 KRRMJKMGWWXWDW-STQMWFEESA-N 0.000 description 11
- MHZXESQPPXOING-KBPBESRZSA-N Gly-Lys-Phe Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O MHZXESQPPXOING-KBPBESRZSA-N 0.000 description 11
- IHDKKJVBLGXLEL-STQMWFEESA-N Gly-Tyr-Met Chemical compound CSCC[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)CN)C(O)=O IHDKKJVBLGXLEL-STQMWFEESA-N 0.000 description 11
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 description 11
- DKDHTRVDOUZZTP-IFFSRLJSSA-N Thr-Gln-Val Chemical compound CC(C)[C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)[C@@H](C)O)C(O)=O DKDHTRVDOUZZTP-IFFSRLJSSA-N 0.000 description 11
- FQPDRTDDEZXCEC-SVSWQMSJSA-N Thr-Ile-Ser Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O FQPDRTDDEZXCEC-SVSWQMSJSA-N 0.000 description 11
- AKHDFZHUPGVFEJ-YEPSODPASA-N Thr-Val-Gly Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)NCC(O)=O AKHDFZHUPGVFEJ-YEPSODPASA-N 0.000 description 11
- 238000005406 washing Methods 0.000 description 11
- NKBQZKVMKJJDLX-SRVKXCTJSA-N Arg-Glu-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(O)=O NKBQZKVMKJJDLX-SRVKXCTJSA-N 0.000 description 10
- MYVBTYXSWILFCG-BQBZGAKWSA-N Asn-Met-Gly Chemical compound CSCC[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N MYVBTYXSWILFCG-BQBZGAKWSA-N 0.000 description 10
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 description 10
- FQCILXROGNOZON-YUMQZZPRSA-N Gln-Pro-Gly Chemical compound NC(=O)CC[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O FQCILXROGNOZON-YUMQZZPRSA-N 0.000 description 10
- YQPFCZVKMUVZIN-AUTRQRHGSA-N Glu-Val-Gln Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O YQPFCZVKMUVZIN-AUTRQRHGSA-N 0.000 description 10
- MIIVFRCYJABHTQ-ONGXEEELSA-N Gly-Leu-Val Chemical compound [H]NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O MIIVFRCYJABHTQ-ONGXEEELSA-N 0.000 description 10
- FHQRLHFYVZAQHU-IUCAKERBSA-N Gly-Lys-Gln Chemical compound [H]NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(O)=O FHQRLHFYVZAQHU-IUCAKERBSA-N 0.000 description 10
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 description 10
- VQPPIMUZCZCOIL-GUBZILKMSA-N Leu-Gln-Ala Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(O)=O VQPPIMUZCZCOIL-GUBZILKMSA-N 0.000 description 10
- KIZIOFNVSOSKJI-CIUDSAMLSA-N Leu-Ser-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O)N KIZIOFNVSOSKJI-CIUDSAMLSA-N 0.000 description 10
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 10
- UOLGINIHBRIECN-FXQIFTODSA-N Ser-Glu-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O UOLGINIHBRIECN-FXQIFTODSA-N 0.000 description 10
- YMTLKLXDFCSCNX-BYPYZUCNSA-N Ser-Gly-Gly Chemical compound OC[C@H](N)C(=O)NCC(=O)NCC(O)=O YMTLKLXDFCSCNX-BYPYZUCNSA-N 0.000 description 10
- QYSFWUIXDFJUDW-DCAQKATOSA-N Ser-Leu-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QYSFWUIXDFJUDW-DCAQKATOSA-N 0.000 description 10
- DWYAUVCQDTZIJI-VZFHVOOUSA-N Thr-Ala-Ser Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O DWYAUVCQDTZIJI-VZFHVOOUSA-N 0.000 description 10
- SVGAWGVHFIYAEE-JSGCOSHPSA-N Trp-Gly-Gln Chemical compound C1=CC=C2C(C[C@H](N)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(O)=O)=CNC2=C1 SVGAWGVHFIYAEE-JSGCOSHPSA-N 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- AJBVYEYZVYPFCF-CIUDSAMLSA-N Ala-Lys-Asn Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O AJBVYEYZVYPFCF-CIUDSAMLSA-N 0.000 description 9
- JSHWXQIZOCVWIA-ZKWXMUAHSA-N Asp-Ser-Val Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O JSHWXQIZOCVWIA-ZKWXMUAHSA-N 0.000 description 9
- VNNRLUNBJSWZPF-ZKWXMUAHSA-N Gly-Ser-Ile Chemical compound [H]NCC(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O VNNRLUNBJSWZPF-ZKWXMUAHSA-N 0.000 description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 9
- CKJACGQPCPMWIT-UFYCRDLUSA-N Phe-Pro-Phe Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CKJACGQPCPMWIT-UFYCRDLUSA-N 0.000 description 9
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 9
- JKGGPMOUIAAJAA-YEPSODPASA-N Thr-Gly-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O JKGGPMOUIAAJAA-YEPSODPASA-N 0.000 description 9
- BKIOKSLLAAZYTC-KKHAAJSZSA-N Thr-Val-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O BKIOKSLLAAZYTC-KKHAAJSZSA-N 0.000 description 9
- ANHVRCNNGJMJNG-BZSNNMDCSA-N Tyr-Tyr-Cys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CS)C(=O)O)N)O ANHVRCNNGJMJNG-BZSNNMDCSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 108010069495 cysteinyltyrosine Proteins 0.000 description 9
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 9
- 238000006386 neutralization reaction Methods 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 108010073969 valyllysine Proteins 0.000 description 9
- 108010009962 valyltyrosine Proteins 0.000 description 9
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000012216 screening Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- NKLRWRRVYGQNIH-GHCJXIJMSA-N Asn-Ile-Ala Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O NKLRWRRVYGQNIH-GHCJXIJMSA-N 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- SITLTJHOQZFJGG-UHFFFAOYSA-N N-L-alpha-glutamyl-L-valine Natural products CC(C)C(C(O)=O)NC(=O)C(N)CCC(O)=O SITLTJHOQZFJGG-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000002671 adjuvant Substances 0.000 description 6
- 108010092854 aspartyllysine Proteins 0.000 description 6
- 239000011248 coating agent Substances 0.000 description 6
- 238000000576 coating method Methods 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000002965 ELISA Methods 0.000 description 5
- 241000880493 Leptailurus serval Species 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 238000007865 diluting Methods 0.000 description 5
- 239000012634 fragment Substances 0.000 description 5
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- BYXHQQCXAJARLQ-ZLUOBGJFSA-N Ala-Ala-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(O)=O BYXHQQCXAJARLQ-ZLUOBGJFSA-N 0.000 description 4
- 241000282836 Camelus dromedarius Species 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- DCHQYSOGURGJST-FJXKBIBVSA-N Pro-Thr-Gly Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(O)=O DCHQYSOGURGJST-FJXKBIBVSA-N 0.000 description 4
- FUOGXAQMNJMBFG-WPRPVWTQSA-N Pro-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H]1CCCN1 FUOGXAQMNJMBFG-WPRPVWTQSA-N 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000003053 immunization Effects 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000009465 prokaryotic expression Effects 0.000 description 4
- 108700042769 prolyl-leucyl-glycine Proteins 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- IESDGNYHXIOKRW-YXMSTPNBSA-N (2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s,3r)-2-amino-3-hydroxybutanoyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-(diaminomethylideneamino)pentanoic acid Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-YXMSTPNBSA-N 0.000 description 3
- DIBLBAURNYJYBF-XLXZRNDBSA-N (2s)-2-[[(2s)-2-[[2-[[(2s)-6-amino-2-[[(2s)-2-amino-3-methylbutanoyl]amino]hexanoyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-3-(4-hydroxyphenyl)propanoic acid Chemical compound C([C@H](NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=CC=C1 DIBLBAURNYJYBF-XLXZRNDBSA-N 0.000 description 3
- YLTKNGYYPIWKHZ-ACZMJKKPSA-N Ala-Ala-Glu Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCC(O)=O YLTKNGYYPIWKHZ-ACZMJKKPSA-N 0.000 description 3
- OYJCVIGKMXUVKB-GARJFASQSA-N Ala-Leu-Pro Chemical compound C[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N OYJCVIGKMXUVKB-GARJFASQSA-N 0.000 description 3
- IORKCNUBHNIMKY-CIUDSAMLSA-N Ala-Pro-Glu Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O IORKCNUBHNIMKY-CIUDSAMLSA-N 0.000 description 3
- COXMUHNBYCVVRG-DCAQKATOSA-N Arg-Leu-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(O)=O COXMUHNBYCVVRG-DCAQKATOSA-N 0.000 description 3
- SLKLLQWZQHXYSV-CIUDSAMLSA-N Asn-Ala-Lys Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(O)=O SLKLLQWZQHXYSV-CIUDSAMLSA-N 0.000 description 3
- OLVIPTLKNSAYRJ-YUMQZZPRSA-N Asn-Gly-Lys Chemical compound C(CCN)C[C@@H](C(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)N OLVIPTLKNSAYRJ-YUMQZZPRSA-N 0.000 description 3
- PNHQRQTVBRDIEF-CIUDSAMLSA-N Asn-Leu-Ala Chemical compound C[C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(=O)N)N PNHQRQTVBRDIEF-CIUDSAMLSA-N 0.000 description 3
- LGCVSPFCFXWUEY-IHPCNDPISA-N Asn-Trp-Tyr Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)O)NC(=O)[C@H](CC(=O)N)N LGCVSPFCFXWUEY-IHPCNDPISA-N 0.000 description 3
- PDECQIHABNQRHN-GUBZILKMSA-N Asp-Glu-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC(O)=O PDECQIHABNQRHN-GUBZILKMSA-N 0.000 description 3
- SNDBKTFJWVEVPO-WHFBIAKZSA-N Asp-Gly-Ser Chemical compound [H]N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(O)=O SNDBKTFJWVEVPO-WHFBIAKZSA-N 0.000 description 3
- AHWRSSLYSGLBGD-CIUDSAMLSA-N Asp-Pro-Glu Chemical compound OC(=O)C[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(O)=O AHWRSSLYSGLBGD-CIUDSAMLSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- ZXCAQANTQWBICD-DCAQKATOSA-N Cys-Lys-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CS)N ZXCAQANTQWBICD-DCAQKATOSA-N 0.000 description 3
- NRVQLLDIJJEIIZ-VZFHVOOUSA-N Cys-Thr-Ala Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](C)C(=O)O)NC(=O)[C@H](CS)N)O NRVQLLDIJJEIIZ-VZFHVOOUSA-N 0.000 description 3
- SHERTACNJPYHAR-ACZMJKKPSA-N Gln-Ala-Ser Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(N)=O SHERTACNJPYHAR-ACZMJKKPSA-N 0.000 description 3
- DHNWZLGBTPUTQQ-QEJZJMRPSA-N Gln-Asp-Trp Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)N)N DHNWZLGBTPUTQQ-QEJZJMRPSA-N 0.000 description 3
- CSMHMEATMDCQNY-DZKIICNBSA-N Gln-Val-Tyr Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O CSMHMEATMDCQNY-DZKIICNBSA-N 0.000 description 3
- ITYRYNUZHPNCIK-GUBZILKMSA-N Glu-Ala-Leu Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(O)=O ITYRYNUZHPNCIK-GUBZILKMSA-N 0.000 description 3
- GLWXKFRTOHKGIT-ACZMJKKPSA-N Glu-Asn-Asn Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O GLWXKFRTOHKGIT-ACZMJKKPSA-N 0.000 description 3
- HNVFSTLPVJWIDV-CIUDSAMLSA-N Glu-Glu-Gln Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(O)=O HNVFSTLPVJWIDV-CIUDSAMLSA-N 0.000 description 3
- GJBUAAAIZSRCDC-GVXVVHGQSA-N Glu-Leu-Val Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(O)=O GJBUAAAIZSRCDC-GVXVVHGQSA-N 0.000 description 3
- ALMBZBOCGSVSAI-ACZMJKKPSA-N Glu-Ser-Asn Chemical compound C(CC(=O)O)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)O)N ALMBZBOCGSVSAI-ACZMJKKPSA-N 0.000 description 3
- MFYLRRCYBBJYPI-JYJNAYRXSA-N Glu-Tyr-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CCC(=O)O)N)O MFYLRRCYBBJYPI-JYJNAYRXSA-N 0.000 description 3
- ZALGPUWUVHOGAE-GVXVVHGQSA-N Glu-Val-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](CCC(=O)O)N ZALGPUWUVHOGAE-GVXVVHGQSA-N 0.000 description 3
- GRIRDMVMJJDZKV-RCOVLWMOSA-N Gly-Asn-Val Chemical compound [H]NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O GRIRDMVMJJDZKV-RCOVLWMOSA-N 0.000 description 3
- PABFFPWEJMEVEC-JGVFFNPUSA-N Gly-Gln-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCC(=O)N)NC(=O)CN)C(=O)O PABFFPWEJMEVEC-JGVFFNPUSA-N 0.000 description 3
- YWAQATDNEKZFFK-BYPYZUCNSA-N Gly-Gly-Ser Chemical compound NCC(=O)NCC(=O)N[C@@H](CO)C(O)=O YWAQATDNEKZFFK-BYPYZUCNSA-N 0.000 description 3
- INLIXXRWNUKVCF-JTQLQIEISA-N Gly-Gly-Tyr Chemical compound NCC(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 INLIXXRWNUKVCF-JTQLQIEISA-N 0.000 description 3
- IZVICCORZOSGPT-JSGCOSHPSA-N Gly-Val-Tyr Chemical compound [H]NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O IZVICCORZOSGPT-JSGCOSHPSA-N 0.000 description 3
- WMKXFMUJRCEGRP-SRVKXCTJSA-N His-Asn-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N WMKXFMUJRCEGRP-SRVKXCTJSA-N 0.000 description 3
- FHPZJWJWTWZKNA-LLLHUVSDSA-N Ile-Phe-Pro Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N2CCC[C@@H]2C(=O)O)N FHPZJWJWTWZKNA-LLLHUVSDSA-N 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010065920 Insulin Lispro Proteins 0.000 description 3
- MLTRLIITQPXHBJ-BQBZGAKWSA-N Leu-Asn Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC(N)=O MLTRLIITQPXHBJ-BQBZGAKWSA-N 0.000 description 3
- WUFYAPWIHCUMLL-CIUDSAMLSA-N Leu-Asn-Ala Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(O)=O WUFYAPWIHCUMLL-CIUDSAMLSA-N 0.000 description 3
- VCSBGUACOYUIGD-CIUDSAMLSA-N Leu-Asn-Asp Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(O)=O VCSBGUACOYUIGD-CIUDSAMLSA-N 0.000 description 3
- PVMPDMIKUVNOBD-CIUDSAMLSA-N Leu-Asp-Ser Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O PVMPDMIKUVNOBD-CIUDSAMLSA-N 0.000 description 3
- VWHGTYCRDRBSFI-ZETCQYMHSA-N Leu-Gly-Gly Chemical compound CC(C)C[C@H](N)C(=O)NCC(=O)NCC(O)=O VWHGTYCRDRBSFI-ZETCQYMHSA-N 0.000 description 3
- AUNMOHYWTAPQLA-XUXIUFHCSA-N Leu-Met-Ile Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O AUNMOHYWTAPQLA-XUXIUFHCSA-N 0.000 description 3
- SBANPBVRHYIMRR-GARJFASQSA-N Leu-Ser-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CO)C(=O)N1CCC[C@@H]1C(=O)O)N SBANPBVRHYIMRR-GARJFASQSA-N 0.000 description 3
- SBANPBVRHYIMRR-UHFFFAOYSA-N Leu-Ser-Pro Natural products CC(C)CC(N)C(=O)NC(CO)C(=O)N1CCCC1C(O)=O SBANPBVRHYIMRR-UHFFFAOYSA-N 0.000 description 3
- QUCDKEKDPYISNX-HJGDQZAQSA-N Lys-Asn-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O QUCDKEKDPYISNX-HJGDQZAQSA-N 0.000 description 3
- WTZUSCUIVPVCRH-SRVKXCTJSA-N Lys-Gln-Arg Chemical compound NCCCC[C@H](N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(O)=O)CCCN=C(N)N WTZUSCUIVPVCRH-SRVKXCTJSA-N 0.000 description 3
- XNKDCYABMBBEKN-IUCAKERBSA-N Lys-Gly-Gln Chemical compound NCCCC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCC(N)=O XNKDCYABMBBEKN-IUCAKERBSA-N 0.000 description 3
- WQDKIVRHTQYJSN-DCAQKATOSA-N Lys-Ser-Arg Chemical compound C(CCN)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WQDKIVRHTQYJSN-DCAQKATOSA-N 0.000 description 3
- IOQWIOPSKJOEKI-SRVKXCTJSA-N Lys-Ser-Leu Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(O)=O IOQWIOPSKJOEKI-SRVKXCTJSA-N 0.000 description 3
- IEVXCWPVBYCJRZ-IXOXFDKPSA-N Lys-Thr-His Chemical compound NCCCC[C@H](N)C(=O)N[C@@H]([C@H](O)C)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 IEVXCWPVBYCJRZ-IXOXFDKPSA-N 0.000 description 3
- DLCAXBGXGOVUCD-PPCPHDFISA-N Lys-Thr-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O DLCAXBGXGOVUCD-PPCPHDFISA-N 0.000 description 3
- SXWQMBGNFXAGAT-FJXKBIBVSA-N Met-Gly-Thr Chemical compound CSCC[C@H](N)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(O)=O SXWQMBGNFXAGAT-FJXKBIBVSA-N 0.000 description 3
- KYXDADPHSNFWQX-VEVYYDQMSA-N Met-Thr-Asp Chemical compound CSCC[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@H](C(O)=O)CC(O)=O KYXDADPHSNFWQX-VEVYYDQMSA-N 0.000 description 3
- YBAFDPFAUTYYRW-UHFFFAOYSA-N N-L-alpha-glutamyl-L-leucine Natural products CC(C)CC(C(O)=O)NC(=O)C(N)CCC(O)=O YBAFDPFAUTYYRW-UHFFFAOYSA-N 0.000 description 3
- KZNQNBZMBZJQJO-UHFFFAOYSA-N N-glycyl-L-proline Natural products NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 3
- HTTYNOXBBOWZTB-SRVKXCTJSA-N Phe-Asn-Asn Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N HTTYNOXBBOWZTB-SRVKXCTJSA-N 0.000 description 3
- MSHZERMPZKCODG-ACRUOGEOSA-N Phe-Leu-Phe Chemical compound C([C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 MSHZERMPZKCODG-ACRUOGEOSA-N 0.000 description 3
- JDMKQHSHKJHAHR-UHFFFAOYSA-N Phe-Phe-Leu-Tyr Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)CC1=CC=CC=C1 JDMKQHSHKJHAHR-UHFFFAOYSA-N 0.000 description 3
- IIEOLPMQYRBZCN-SRVKXCTJSA-N Phe-Ser-Cys Chemical compound N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CS)C(=O)O IIEOLPMQYRBZCN-SRVKXCTJSA-N 0.000 description 3
- IHCXPSYCHXFXKT-DCAQKATOSA-N Pro-Arg-Glu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O IHCXPSYCHXFXKT-DCAQKATOSA-N 0.000 description 3
- TUYWCHPXKQTISF-LPEHRKFASA-N Pro-Cys-Pro Chemical compound C1C[C@H](NC1)C(=O)N[C@@H](CS)C(=O)N2CCC[C@@H]2C(=O)O TUYWCHPXKQTISF-LPEHRKFASA-N 0.000 description 3
- VPEVBAUSTBWQHN-NHCYSSNCSA-N Pro-Glu-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(O)=O VPEVBAUSTBWQHN-NHCYSSNCSA-N 0.000 description 3
- KWMUAKQOVYCQJQ-ZPFDUUQYSA-N Pro-Ile-Glu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)O)NC(=O)[C@@H]1CCCN1 KWMUAKQOVYCQJQ-ZPFDUUQYSA-N 0.000 description 3
- FXGIMYRVJJEIIM-UWVGGRQHSA-N Pro-Leu-Gly Chemical compound OC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H]1CCCN1 FXGIMYRVJJEIIM-UWVGGRQHSA-N 0.000 description 3
- ZLXKLMHAMDENIO-DCAQKATOSA-N Pro-Lys-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLXKLMHAMDENIO-DCAQKATOSA-N 0.000 description 3
- PCWLNNZTBJTZRN-AVGNSLFASA-N Pro-Pro-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 PCWLNNZTBJTZRN-AVGNSLFASA-N 0.000 description 3
- KBUAPZAZPWNYSW-SRVKXCTJSA-N Pro-Pro-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KBUAPZAZPWNYSW-SRVKXCTJSA-N 0.000 description 3
- GOMUXSCOIWIJFP-GUBZILKMSA-N Pro-Ser-Arg Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O GOMUXSCOIWIJFP-GUBZILKMSA-N 0.000 description 3
- GMJDSFYVTAMIBF-FXQIFTODSA-N Pro-Ser-Asp Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(O)=O GMJDSFYVTAMIBF-FXQIFTODSA-N 0.000 description 3
- PRKWBYCXBBSLSK-GUBZILKMSA-N Pro-Ser-Val Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(O)=O PRKWBYCXBBSLSK-GUBZILKMSA-N 0.000 description 3
- OYEDZGNMSBZCIM-XGEHTFHBSA-N Ser-Arg-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(O)=O OYEDZGNMSBZCIM-XGEHTFHBSA-N 0.000 description 3
- VGNYHOBZJKWRGI-CIUDSAMLSA-N Ser-Asn-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CO VGNYHOBZJKWRGI-CIUDSAMLSA-N 0.000 description 3
- UIGMAMGZOJVTDN-WHFBIAKZSA-N Ser-Gly-Ser Chemical compound OC[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O UIGMAMGZOJVTDN-WHFBIAKZSA-N 0.000 description 3
- HMRAQFJFTOLDKW-GUBZILKMSA-N Ser-His-Glu Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCC(O)=O)C(O)=O HMRAQFJFTOLDKW-GUBZILKMSA-N 0.000 description 3
- GZSZPKSBVAOGIE-CIUDSAMLSA-N Ser-Lys-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O GZSZPKSBVAOGIE-CIUDSAMLSA-N 0.000 description 3
- ASJDFGOPDCVXTG-KATARQTJSA-N Thr-Cys-Leu Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(C)C)C(O)=O ASJDFGOPDCVXTG-KATARQTJSA-N 0.000 description 3
- KWQBJOUOSNJDRR-XAVMHZPKSA-N Thr-Cys-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CS)C(=O)N1CCC[C@@H]1C(=O)O)N)O KWQBJOUOSNJDRR-XAVMHZPKSA-N 0.000 description 3
- DSLHSTIUAPKERR-XGEHTFHBSA-N Thr-Cys-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(O)=O DSLHSTIUAPKERR-XGEHTFHBSA-N 0.000 description 3
- NCXVJIQMWSGRHY-KXNHARMFSA-N Thr-Leu-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@@H]1C(=O)O)N)O NCXVJIQMWSGRHY-KXNHARMFSA-N 0.000 description 3
- BDGBHYCAZJPLHX-HJGDQZAQSA-N Thr-Lys-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O BDGBHYCAZJPLHX-HJGDQZAQSA-N 0.000 description 3
- BEZTUFWTPVOROW-KJEVXHAQSA-N Thr-Tyr-Arg Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O BEZTUFWTPVOROW-KJEVXHAQSA-N 0.000 description 3
- FYBFTPLPAXZBOY-KKHAAJSZSA-N Thr-Val-Asp Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O FYBFTPLPAXZBOY-KKHAAJSZSA-N 0.000 description 3
- DQDXHYIEITXNJY-BPUTZDHNSA-N Trp-Gln-Gln Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)O)N DQDXHYIEITXNJY-BPUTZDHNSA-N 0.000 description 3
- SCCKSNREWHMKOJ-SRVKXCTJSA-N Tyr-Asn-Ser Chemical compound N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(O)=O SCCKSNREWHMKOJ-SRVKXCTJSA-N 0.000 description 3
- JKUZFODWJGEQAP-KBPBESRZSA-N Tyr-Gly-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)O)N)O JKUZFODWJGEQAP-KBPBESRZSA-N 0.000 description 3
- SINRIKQYQJRGDQ-MEYUZBJRSA-N Tyr-Lys-Thr Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 SINRIKQYQJRGDQ-MEYUZBJRSA-N 0.000 description 3
- NHOVZGFNTGMYMI-KKUMJFAQSA-N Tyr-Ser-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 NHOVZGFNTGMYMI-KKUMJFAQSA-N 0.000 description 3
- RIVVDNTUSRVTQT-IRIUXVKKSA-N Tyr-Thr-Gln Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)[C@H](CC1=CC=C(C=C1)O)N)O RIVVDNTUSRVTQT-IRIUXVKKSA-N 0.000 description 3
- LNYOXPDEIZJDEI-NHCYSSNCSA-N Val-Asn-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)N)NC(=O)[C@H](C(C)C)N LNYOXPDEIZJDEI-NHCYSSNCSA-N 0.000 description 3
- QHDXUYOYTPWCSK-RCOVLWMOSA-N Val-Asp-Gly Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)O)N QHDXUYOYTPWCSK-RCOVLWMOSA-N 0.000 description 3
- VFOHXOLPLACADK-GVXVVHGQSA-N Val-Gln-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CCC(=O)N)NC(=O)[C@H](C(C)C)N VFOHXOLPLACADK-GVXVVHGQSA-N 0.000 description 3
- AGKDVLSDNSTLFA-UMNHJUIQSA-N Val-Gln-Pro Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N AGKDVLSDNSTLFA-UMNHJUIQSA-N 0.000 description 3
- RKIGNDAHUOOIMJ-BQFCYCMXSA-N Val-Glu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)C(C)C)C(O)=O)=CNC2=C1 RKIGNDAHUOOIMJ-BQFCYCMXSA-N 0.000 description 3
- XTDDIVQWDXMRJL-IHRRRGAJSA-N Val-Leu-His Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)NC(=O)[C@H](C(C)C)N XTDDIVQWDXMRJL-IHRRRGAJSA-N 0.000 description 3
- SYSWVVCYSXBVJG-RHYQMDGZSA-N Val-Leu-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)N)O SYSWVVCYSXBVJG-RHYQMDGZSA-N 0.000 description 3
- HPANGHISDXDUQY-ULQDDVLXSA-N Val-Lys-Phe Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)O)N HPANGHISDXDUQY-ULQDDVLXSA-N 0.000 description 3
- SBJCTAZFSZXWSR-AVGNSLFASA-N Val-Met-His Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CN=CN1)C(=O)O)N SBJCTAZFSZXWSR-AVGNSLFASA-N 0.000 description 3
- VHIZXDZMTDVFGX-DCAQKATOSA-N Val-Ser-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N VHIZXDZMTDVFGX-DCAQKATOSA-N 0.000 description 3
- ZLNYBMWGPOKSLW-LSJOCFKGSA-N Val-Val-Asp Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O ZLNYBMWGPOKSLW-LSJOCFKGSA-N 0.000 description 3
- LLJLBRRXKZTTRD-GUBZILKMSA-N Val-Val-Ser Chemical compound CC(C)[C@@H](C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CO)C(=O)O)N LLJLBRRXKZTTRD-GUBZILKMSA-N 0.000 description 3
- 241001416177 Vicugna pacos Species 0.000 description 3
- 238000001261 affinity purification Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 108010013835 arginine glutamate Proteins 0.000 description 3
- 108010052670 arginyl-glutamyl-glutamic acid Proteins 0.000 description 3
- 210000000170 cell membrane Anatomy 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 108010013768 glutamyl-aspartyl-proline Proteins 0.000 description 3
- 108010015792 glycyllysine Proteins 0.000 description 3
- 238000002649 immunization Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 108010044311 leucyl-glycyl-glycine Proteins 0.000 description 3
- 108010073472 leucyl-prolyl-proline Proteins 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 108010070643 prolylglutamic acid Proteins 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 108010048397 seryl-lysyl-leucine Proteins 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108010080629 tryptophan-leucine Proteins 0.000 description 3
- 108010003137 tyrosyltyrosine Proteins 0.000 description 3
- 108010052774 valyl-lysyl-glycyl-phenylalanyl-tyrosine Proteins 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- BUDNAJYVCUHLSV-ZLUOBGJFSA-N Ala-Asp-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O BUDNAJYVCUHLSV-ZLUOBGJFSA-N 0.000 description 2
- KUFVXLQLDHJVOG-SHGPDSBTSA-N Ala-Thr-Thr Chemical compound C[C@H]([C@@H](C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@H](C)N)O KUFVXLQLDHJVOG-SHGPDSBTSA-N 0.000 description 2
- 101710117290 Aldo-keto reductase family 1 member C4 Proteins 0.000 description 2
- PRLPSDIHSRITSF-UNQGMJICSA-N Arg-Phe-Thr Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(O)=O PRLPSDIHSRITSF-UNQGMJICSA-N 0.000 description 2
- YNQIDCRRTWGHJD-ZLUOBGJFSA-N Asp-Asn-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CC(O)=O YNQIDCRRTWGHJD-ZLUOBGJFSA-N 0.000 description 2
- HTSSXFASOUSJQG-IHPCNDPISA-N Asp-Tyr-Trp Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HTSSXFASOUSJQG-IHPCNDPISA-N 0.000 description 2
- 241000282832 Camelidae Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108091006027 G proteins Proteins 0.000 description 2
- 102000030782 GTP binding Human genes 0.000 description 2
- 108091000058 GTP-Binding Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- BYYNJRSNDARRBX-YFKPBYRVSA-N Gly-Gln-Gly Chemical compound NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(O)=O BYYNJRSNDARRBX-YFKPBYRVSA-N 0.000 description 2
- NTXIJPDAHXSHNL-ONGXEEELSA-N His-Gly-Val Chemical compound [H]N[C@@H](CC1=CNC=N1)C(=O)NCC(=O)N[C@@H](C(C)C)C(O)=O NTXIJPDAHXSHNL-ONGXEEELSA-N 0.000 description 2
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 2
- JHNJNTMTZHEDLJ-NAKRPEOUSA-N Ile-Ser-Arg Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(O)=O JHNJNTMTZHEDLJ-NAKRPEOUSA-N 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- LGIMRDKGABDMBN-DCAQKATOSA-N Ser-Val-Lys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N LGIMRDKGABDMBN-DCAQKATOSA-N 0.000 description 2
- 230000024932 T cell mediated immunity Effects 0.000 description 2
- BODHJXJNRVRKFA-BZSNNMDCSA-N Tyr-Cys-Tyr Chemical compound [H]N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(O)=O BODHJXJNRVRKFA-BZSNNMDCSA-N 0.000 description 2
- DIOSYUIWOQCXNR-ONGXEEELSA-N Val-Lys-Gly Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)NCC(O)=O DIOSYUIWOQCXNR-ONGXEEELSA-N 0.000 description 2
- 238000007605 air drying Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 230000000120 cytopathologic effect Effects 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000001976 enzyme digestion Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 230000002637 immunotoxin Effects 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 231100000608 immunotoxin Toxicity 0.000 description 2
- 229940051026 immunotoxin Drugs 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 208000030500 lower respiratory tract disease Diseases 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004091 panning Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 210000005105 peripheral blood lymphocyte Anatomy 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 108010061238 threonyl-glycine Proteins 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 108010038745 tryptophylglycine Proteins 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- OTLLEIBWKHEHGU-UHFFFAOYSA-N 2-[5-[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy]-3,4-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-4-phosphonooxyhexanedioic acid Chemical compound C1=NC=2C(N)=NC=NC=2N1C(C(C1O)O)OC1COC1C(CO)OC(OC(C(O)C(OP(O)(O)=O)C(O)C(O)=O)C(O)=O)C(O)C1O OTLLEIBWKHEHGU-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- 108010066676 Abrin Proteins 0.000 description 1
- 229930195730 Aflatoxin Natural products 0.000 description 1
- XWIYFDMXXLINPU-UHFFFAOYSA-N Aflatoxin G Chemical compound O=C1OCCC2=C1C(=O)OC1=C2C(OC)=CC2=C1C1C=COC1O2 XWIYFDMXXLINPU-UHFFFAOYSA-N 0.000 description 1
- 101710186708 Agglutinin Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- HFPXZWPUVFVNLL-GUBZILKMSA-N Asn-Leu-Gln Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O HFPXZWPUVFVNLL-GUBZILKMSA-N 0.000 description 1
- BCADFFUQHIMQAA-KKHAAJSZSA-N Asn-Thr-Val Chemical compound [H]N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O BCADFFUQHIMQAA-KKHAAJSZSA-N 0.000 description 1
- CLUMZOKVGUWUFD-CIUDSAMLSA-N Asp-Leu-Asn Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O CLUMZOKVGUWUFD-CIUDSAMLSA-N 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000016607 Diphtheria Toxin Human genes 0.000 description 1
- 108010053187 Diphtheria Toxin Proteins 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 235000014066 European mistletoe Nutrition 0.000 description 1
- 108010008177 Fd immunoglobulins Proteins 0.000 description 1
- 101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- SBCYJMOOHUDWDA-NUMRIWBASA-N Glu-Asp-Thr Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O SBCYJMOOHUDWDA-NUMRIWBASA-N 0.000 description 1
- CQMFNTVQVLQRLT-JHEQGTHGSA-N Gly-Thr-Gln Chemical compound [H]NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O CQMFNTVQVLQRLT-JHEQGTHGSA-N 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101710146024 Horcolin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- YPQDTQJBOFOTJQ-SXTJYALSSA-N Ile-Asn-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)N YPQDTQJBOFOTJQ-SXTJYALSSA-N 0.000 description 1
- XENGULNPUDGALZ-ZPFDUUQYSA-N Ile-Asn-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)O)N XENGULNPUDGALZ-ZPFDUUQYSA-N 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 101710189395 Lectin Proteins 0.000 description 1
- WGNOPSQMIQERPK-GARJFASQSA-N Leu-Asn-Pro Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N1CCC[C@@H]1C(=O)O)N WGNOPSQMIQERPK-GARJFASQSA-N 0.000 description 1
- 235000003956 Luffa Nutrition 0.000 description 1
- 244000050983 Luffa operculata Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 101710179758 Mannose-specific lectin Proteins 0.000 description 1
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 description 1
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 description 1
- FRWZTWWOORIIBA-FXQIFTODSA-N Met-Asn-Asn Chemical compound CSCC[C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)O)N FRWZTWWOORIIBA-FXQIFTODSA-N 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 241000711504 Paramyxoviridae Species 0.000 description 1
- WWPAHTZOWURIMR-ULQDDVLXSA-N Phe-Pro-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@@H](N)CC1=CC=CC=C1 WWPAHTZOWURIMR-ULQDDVLXSA-N 0.000 description 1
- XOHJOMKCRLHGCY-UNQGMJICSA-N Phe-Pro-Thr Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(O)=O XOHJOMKCRLHGCY-UNQGMJICSA-N 0.000 description 1
- ZLAKUZDMKVKFAI-JYJNAYRXSA-N Phe-Pro-Val Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(O)=O ZLAKUZDMKVKFAI-JYJNAYRXSA-N 0.000 description 1
- 241000711902 Pneumovirus Species 0.000 description 1
- VGVCNKSUVSZEIE-IHRRRGAJSA-N Pro-Phe-Asn Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(N)=O)C(O)=O VGVCNKSUVSZEIE-IHRRRGAJSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 235000012300 Rhipsalis cassutha Nutrition 0.000 description 1
- 102000004389 Ribonucleoproteins Human genes 0.000 description 1
- 108010081734 Ribonucleoproteins Proteins 0.000 description 1
- 108010039491 Ricin Proteins 0.000 description 1
- LWMQRHDTXHQQOV-MXAVVETBSA-N Ser-Ile-Phe Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC1=CC=CC=C1)C(O)=O LWMQRHDTXHQQOV-MXAVVETBSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 102100021696 Syncytin-1 Human genes 0.000 description 1
- SLLKXDSRVAOREO-KZVJFYERSA-N Val-Ala-Thr Chemical compound C[C@H]([C@@H](C(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C(C)C)N)O SLLKXDSRVAOREO-KZVJFYERSA-N 0.000 description 1
- HTONZBWRYUKUKC-RCWTZXSCSA-N Val-Thr-Val Chemical compound CC(C)[C@H](N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O HTONZBWRYUKUKC-RCWTZXSCSA-N 0.000 description 1
- OWFGFHQMSBTKLX-UFYCRDLUSA-N Val-Tyr-Tyr Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CC1=CC=C(C=C1)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)O)N OWFGFHQMSBTKLX-UFYCRDLUSA-N 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000221012 Viscum Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000005409 aflatoxin Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 239000000910 agglutinin Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000012930 cell culture fluid Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000003235 crystal violet staining Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 102000034287 fluorescent proteins Human genes 0.000 description 1
- 108091006047 fluorescent proteins Proteins 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical group [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000000710 homodimer Substances 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 235000014380 magnesium carbonate Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002941 microtiter virus yield reduction assay Methods 0.000 description 1
- 108010010621 modeccin Proteins 0.000 description 1
- 210000004897 n-terminal region Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 238000011587 new zealand white rabbit Methods 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108040000983 polyphosphate:AMP phosphotransferase activity proteins Proteins 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000012192 staining solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/115—Paramyxoviridae, e.g. parainfluenza virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
Abstract
本发明涉及生物医药领域，特别涉及针对RSV病毒F蛋白的纳米抗体、其编码序列在诊断和治疗中的应用。本发明提供的RSV纳米抗体具有独特的CDR1、2和3区序列，使所述抗体对RSV抗原具有特异的识别和结合能力。而与其他非特异性蛋白无交叉反应。通过中和活性检测，其显示了良好的中和活性，可单独或与其他药物或抗体等联合应用，用于制备RSV治疗性药物。
Description
技术领域
本发明涉及生物医药领域，特别涉及针对RSV病毒F蛋白的纳米抗体、其编码序列在诊断和治疗中的应用。
背景技术
呼吸道合胞病毒(respiratory syncytial virus，RSV)是导致婴幼儿、老年人和免疫力低下的个体严重下呼吸道疾病的主要病因。RSV感染呼吸道黏膜上皮细胞，病毒蛋白能在胞内引起复杂的信号传导，导致各种细胞因子表达异常，这可能是导致严重下呼吸道疾病的原因。相关灭活疫苗加重疾病的重要特征是诱导相关细胞因子大量分泌，从而引起不平衡的体液免疫和细胞免疫应答。
RSV属副粘病毒科肺炎病毒属，基因组为单股负链RNA，编码11种蛋白质，其中3个为跨膜包膜糖蛋白F蛋白(fusion protein)、G蛋白(attachmentprotein)和SH蛋白(smallhydrophobic protein)，根据G蛋白抗原性的不同，将RSV分为A、B两个亚型。F蛋白通过介导RSV与宿主细胞膜融合导致RSV核糖核蛋白穿入到细胞浆。感染后，表达在细胞膜上的F蛋白可促进感染细胞与邻近细胞细胞膜融合形成合胞体。
F蛋白在RSV不同亚型间具有高度的抗原同源性，是主要的交叉保护性抗原，同时还是细胞毒性T淋巴细胞(CTL)的主要靶抗原，因此，F蛋白是机体免疫系统重要的靶抗原，可介导产生保护性抗体和细胞免疫反应，且能提供交叉保护作用。F是RSV最主要的表面结构蛋白之一，作为最重要的中和抗原，F蛋白具有大量的中和抗体识别表位。
单克隆抗体在一些应用方面仍存在缺陷：分子质量大(150kDa)限制其组织穿透能力；在体内能够引起免疫反应，进而中和抗体活性；半衰期较长限制其在分子成像中的应用；生产操作复杂、生产成本高。
1993年，科学家在骆驼体内发现天然缺失轻链的重链抗体(Heavy chainantibodies，HcAbs)，其抗原结合域可变区，也被称为VHH或纳米抗体(nanobody，Nb)，为抗体小型化研究提供了新的发展方向。随后，软体鱼类体内也发现了骆驼体内类似的抗原受体(new antigen receptor，NAR)。与其他小分子抗体相比，纳米抗体具有如分子质量小(12～15kDa)、亲和力高、免疫源性低、可溶性好、稳定性好、表达量高等独特的性质，使其在疾病诊断及治疗方面更具优势。因此，提供针对于RSV病毒F蛋白的纳米抗体、其编码序列在诊断和治疗中的应用具有重要的现实意义。
发明内容
有鉴于此，本发明提供了针对RSV病毒F蛋白的纳米抗体、其编码序列在诊断和治疗中的应用。
为了实现上述发明目的，本发明提供以下技术方案：
本发明提供了纳米抗体，所述纳米抗体包括三个互补决定区CDR1、CDR2、CDR3；其中
(I)、所述纳米抗体的互补决定区CDR1具有如SEQ ID No.1所示的氨基酸序列；和/或
所述纳米抗体的互补决定区CDR2具有如SEQ ID No.2或3所示的氨基酸序列；和/或
所述纳米抗体的互补决定区CDR3具有如SEQ ID No.4～6任一项所示的氨基酸序列；
或(II)、如(I)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(I)所述氨基酸序列功能相同的氨基酸序列；
或(III)、与(I)或(II)所述氨基酸序列具有80％以上同一性的氨基酸序列。
在本发明的一些具体实施方案中，所述纳米抗体还包括四个恒定区FR1、FR2、FR3、FR4，其中，
(IV)、所述纳米抗体的恒定区FR1具有如SEQ ID No.7所示的氨基酸序列；和/或
所述纳米抗体的恒定区FR2具有如SEQ ID No.8所示的氨基酸序列；和/或
所述纳米抗体的恒定区FR3具有如SEQ ID No.9所示的氨基酸序列；和/或
所述纳米抗体的恒定区FR4具有如SEQ ID No.10所示的氨基酸序列；
或(V)、如(IV)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(IV)所述氨基酸序列功能相同的氨基酸序列；
或(VI)、与(IV)或(V)所述氨基酸序列具有80％以上同一性的氨基酸序列。
在本发明的一些具体实施方案中，
(VII)、所述纳米抗体具有如SEQ ID No.11～13中任一项所示的氨基酸序列；
或
(VIII)、如(VII)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(VII)所述氨基酸序列功能相同的氨基酸序列；
或
(IX)、与(VII)或(VIII)所述氨基酸序列具有80％以上同一性的氨基酸序列。
本发明还提供了所述的纳米抗体的二聚体，
(X)、所述纳米抗体的二聚体具有如SEQ ID No.14～16中任一项所示的氨基酸序列；
或
(XI)、如(X)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(X)所述氨基酸序列功能相同的氨基酸序列；
或
(XII)、与(X)或(XI)所述氨基酸序列具有80％以上同一性的氨基酸序列。
本发明还提供了人源化RSV纳米抗体，
(XIII)、所述人源化RSV纳米抗体具有如SEQ ID No.17～19中任一项所示的氨基酸序列；
或
(XIV)、如(XIII)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(XIII)所述氨基酸序列功能相同的氨基酸序列；
或
(XV)、与(XIII)或(XIV)所述氨基酸序列具有80％以上同一性的氨基酸序列。
本发明中，所述多个为2个、3个、4个或5个。
基于上述研究，本发明还提供了编码所述的纳米抗体、编码所述的纳米抗体的二聚体或编码所述的人源化RSV纳米抗体的核苷酸。
本发明还提供了一种表达载体，包括所述的核苷酸。
此外，本发明还提供了转化或转染所述的表达载体的宿主细胞。
本发明还提供了结合物，包含经化学标记或生物标记的所述的纳米抗体、所述的纳米抗体的二聚体或所述的人源化RSV纳米抗体。
在本发明中，所述化学标记为同位素、免疫毒素和/或化学药物；所述生物标记为生物素、亲和素或酶标记。所述酶标记优选为辣根过氧化物酶或碱性磷酸酶。所述免疫毒素优选为黄曲霉毒素、白喉毒素、绿脓杆菌外毒素、蓖麻毒蛋白、相思子毒蛋白、槲寄生凝集素、蒴莲根毒素、PAP、造草素、白树毒素或丝瓜毒素。
基于上述研究，本发明还提供了所述的纳米抗体、所述的纳米抗体的二聚体、所述的人源化RSV纳米抗体或所述的结合物与固体介质或半固体介质偶联制得的偶联物。
在本发明中，所述固体介质或非固体介质选自胶体金、聚苯乙烯平板或珠粒。
本发明还提供了所述的纳米抗体、所述的纳米抗体的二聚体、所述的人源化RSV纳米抗体、所述的结合物和/或所述的偶联物在制备RSV病毒诊断试剂和/或试剂盒中的应用。
本发明还提供了所述的纳米抗体、所述的纳米抗体的二聚体、所述的人源化RSV纳米抗体、所述的结合物和/或所述的偶联物在制备预防和/或治疗RSV病毒相关疾病的药物中的应用。
基于上述研究，本发明还提供了RSV病毒诊断试剂，包括所述的纳米抗体、所述的纳米抗体的二聚体、所述的人源化RSV纳米抗体、所述的结合物和/或所述的偶联物以及可接受的助剂。
本发明还提供了RSV病毒诊断试剂盒，包括所述的纳米抗体、所述的纳米抗体的二聚体、所述的人源化RSV纳米抗体、所述的结合物和/或所述的偶联物以及可接受的助剂和/或载体。
本发明还提供了疾病的诊断方法，以所述的RSV病毒诊断试剂或所述的RSV病毒诊断试剂盒检测RSV表达，根据表达量判断是否患有疾病。
基于上述研究，本发明还提供了预防和/或治疗RSV病毒相关疾病的药物，包括所述的纳米抗体、所述的纳米抗体的二聚体、所述的人源化RSV纳米抗体、所述的结合物和/或所述的偶联物以及可接受的辅料。
此外，本发明还提供了疾病的预防和/或治疗方法，给予本发明所述的药物。本发明首先将RSV基因工程重组F蛋白免疫骆驼，经过4次免疫之后分离该免疫骆驼外周血淋巴细胞，并构建特异性的RSV基因工程重组F蛋白重链抗体基因文库。将重组F蛋白包被在酶标板上，利用噬菌体展示技术，从免疫后的纳米抗体库中筛选得到了抗重组F蛋白的纳米抗体。构建的纳米抗体原核表达载体，将其导入大肠杆菌，表达后纯化，纯化后的RSV纳米抗体能够与重组F蛋白特异性结合，并能有效中和RSV病毒。
本发明提供的RSV纳米抗体具有独特的CDR1、2和3区序列，使所述抗体对RSV抗原具有特异的识别和结合能力。而与其他非特异性交叉反应性蛋白没有反应。通过中和活性检测，其显示了良好的中和活性，可单独或与其他药物或抗体等联合应用，用于制备RSV治疗性药物。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案，下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍。
图1示单域抗体PCR产物1.5％凝胶鉴定结果；
图2示载体双酶切1％凝胶鉴定结果；
图3示单菌落进行菌液PCR，测定的阳性率结果；
图4示抗体亲和纯化后电泳图谱；
图5示抗体与F蛋白结合活性检测；
图6示单域抗体中和活性检测；
图7示单域抗体人源化和二聚体检测结果；其中，a示4-BF-5；b示12-Fh-46；c示5-Fb-34；
图8示RSV病毒阴性、阳性荧光鉴定照片；其中，a示RSV病毒阴性(-)鉴定照片；b示RSV病毒阳性(+)鉴定照片。
具体实施方式
本发明公开了针对RSV病毒F蛋白的纳米抗体、其编码序列在诊断和治疗中的应用，本领域技术人员可以借鉴本文内容，适当改进工艺参数实现。特别需要指出的是，所有类似的替换和改动对本领域技术人员来说是显而易见的，它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述，相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合，来实现和应用本发明技术。
本发明首先将RSV基因工程重组F蛋白免疫骆驼，经过4次免疫之后分离该免疫骆驼外周血淋巴细胞，并构建特异性的RSV基因工程重组F蛋白重链抗体基因文库。将重组F蛋白包被在酶标板上，利用噬菌体展示技术，从免疫后的纳米抗体库中筛选得到了抗重组F蛋白的纳米抗体。构建的纳米抗体原核表达载体，将其导入大肠杆菌，表达后纯化，纯化后的RSV纳米抗体能够与重组F蛋白特异性结合，并能有效中和RSV病毒。
本发明提供一种可以特异性结合RSV病毒F蛋白的纳米抗体编码序列、其制备方法及应用。
具体而言：
所述纳米抗体可变区具有3个互补决定区CDR1、CDR2、CDR3，其中，
CDR1序列由SEQ ID No.1所述氨基酸序列组成；(不是全人源，是否CDR可以交叉)
CDR2序列由SEQ ID No.2、3所述氨基酸序列组成；
CDR3序列由SEQ ID No.4、5、6所述氨基酸序列组成。
所述纳米抗体还具有恒定区FR1、FR2、FR3、FR4，其中，
FR1序列由SEQ ID No.7所述氨基酸序列组成；
FR2序列由SEQ ID No.8所述氨基酸序列组成；
FR3序列由SEQ ID No.9所述氨基酸序列组成；
FR4序列由SEQ ID No.10所述氨基酸序列组成。
本发明还提供了一种编码上述纳米抗体的氨基酸编码序列，所述编码序列由SEQID No.11～13。
本发明还提供了一种编码上述纳米抗体二聚体序列，所述编码序列含有SEQ IDNo.14～16
本发明还提供了一种编码上述人源化RSV纳米抗体的氨基酸序列，所述编码序列含有SEQ ID No.17～19
本发明提供了上述纳米抗体在制备诊断RSV病毒诊断试剂中的应用。
本发明提供了上述纳米抗体在制备RSV治疗性药物中的应用。
Sequence:
FR1:EVQLQASGGGLVQPGGSLRLSCTASG SEQ ID No.7
FR2:WYRQAPGKQRELVAT SEQ ID No.8
FR3:ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC SEQ ID No.9
FR4:WGQGTQVTVGSEQKLISEEDLN SEQ ID No.10
第二组
>4-BF-5
CDR1:SIFPFNNMG SEQ ID No.1
CDR2:ATTHGVINI SEQ ID No.2
CDR3:YGKFPTGGYMTDY SEQ ID No.4
>12-Fh-46
CDR1:SIFPFNNMG SEQ ID No.1
CDR2:ATTHGVINI SEQ ID No.2
CDR3:YGKFPVGGYMTDY SEQ ID No.5
>5-Fb-34
CDR1:SIFPFNNMG SEQ ID No.1
CDR2:ATTHGVINL SEQ ID No.3
CDR3:YGKFPLGGYMTDY SEQ ID No.6
SEQ No.11-13：
SEQ No.11 EVQLQASGGGLVQPGGSLRLSCTASG SIFPFNNMG WYRQAPGKQRE LVATATTHGVINI ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC YGKFPTG GYMTDYWGQGTQVTVGSEQKLISEEDLN
SEQ No.12 EVQLQASGGGLVQPGGSLRLSCTASG SIFPFNNMG WYRQAPGKQRE LVATATTHGVINI ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC YGKFPVG GYMTDYWGQGTQVTVGSEQKLISEEDLN
SEQ No.13 EVQLQASGGGLVQPGGSLRLSCTASG SIFPFNNMG WYRQAPGKQRE LVATATTHGVINL ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC YGKFPLG GYMTDYWGQGTQVTVGSEQKLISEEDLN
SEQ No.14 EVQLQASGGGLVQPGGSLRLSCTASG SIFPFNNMG WYRQAPGKQRE LVATATTHGVINI ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC YGKFPTG GYMTDYWGQGTQVTVGSEQKLISEEDLN AAA EVQLQASGGGLVQPGGSLRLSCTA SG SIFPFNNMGTWYRQAPGKQRELVAT ATTHGVINI ADSVKGRFTISRDNAKNTVN LQMNNLNPEDTGVYYC YGKFPTGGYMTDYWGQGTQVTVGSEQKLISEEDLN
SEQ No.15 EVQLQASGGGLVQPGGSLRLSCTASG SIFPFNNMG WYRQAPGKQRE LVATATTHGVINI ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC YGKFPVG GYMTDYWGQGTQVTVGSEQKLISEEDLN AAA EVQLQASGGGLVQPGGSLRLSCTA SG SIFPFNNMGTWYRQAPGKQRELVAT ATTHGVINI ADSVKGRFTISRDNAKNTVN LQMNNLNPEDTGVYYC YGKFPVGGYMTDYWGQGTQVTVGSEQKLISEEDLN
SEQ No.16 EVQLQASGGGLVQPGGSLRLSCTASG SIFPFNNMG WYRQAPGKQRE LVATATTHGVINL ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC YGKFPLG GYMTDYWGQGTQVTVGSEQKLISEEDLN AAA EVQLQASGGGLVQPGGSLRLSCTA SG SIFPFNNMGTWYRQAPGKQRELVAT ATTHGVINL ADSVKGRFTISRDNAKNTVN LQMNNLNPEDTGVYY
SEQ No.17 EVQLQASGGGLVQPGGSLRLSCTASG SIFPFNNMG WYRQAPGKQRE LVATATTHGVINI ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC YGKFPTG GYMTDYWGQGTQVTVGSEQKLISEEDLN DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ No.18 EVQLQASGGGLVQPGGSLRLSCTASG SIFPFNNMG WYRQAPGKQRE LVATATTHGVINI ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC YGKFPVG GYMTDYWGQGTQVTVGSEQKLISEEDLN DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
SEQ No.19 EVQLQASGGGLVQPGGSLRLSCTASG SIFPFNNMG WYRQAPGKQRE LVATATTHGVINL ADSVKGRFTISRDNAKNTVNLQMNNLNPEDTGVYYC YGKFPLG GYMTDYWGQGTQVTVGSEQKLISEEDLN DKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK
本发明提供的RSV纳米抗体具有独特的CDR1、2和3区序列，使所述抗体对RSV抗原具有特异的识别和结合能力。而与其他非特异性交叉反应性蛋白没有反应。通过中和活性检测，其显示了良好的中和活性，可单独或与其他药物或抗体等联合应用，用于制备RSV治疗性药物。
除非另有定义，本文使用的所有科技术语具有本领域普通技术人员所理解的相同含义。关于本领域的定义及术语，专业人员具体可参考Current Protocols in MolecularBiology(Ausubel)。氨基酸残基的缩写是本领域中所用的指代20个常用L-氨基酸之一的标准3字母和/或1字母代码。
“抗体”是指由能特异结合抗原的一种或多种多肽构成的蛋白质。抗体的一种形式构成了抗体的基本结构单元。这种形式是四聚物，它由两对完全相同的抗体链构成，每一对都有一个轻链和一个重链。在每对抗体链中，轻链和重链的可变区联合在一起共同负责结合抗原，而恒定区则负责抗体的效应器功能。
“可变区”是该链的N端成熟区域。目前已知的抗体类型包括κ和λ轻链，以及α，γ(IgG1，IgG2，IgG3，IgG4)，δ，ε和μ重链或它们的其它类型等价物。全长的免疫球蛋白“轻链”(大约25kDa或大约214个氨基酸)包含一个由NH2-末端上大约110个氨基酸形成的可变区，以及一个COOH-末端上的κ或λ恒定区。全长的免疫球蛋白“重链”(大约50kDa或大约446个氨基酸)，同样包含一个可变区(大约116个氨基酸)，以及重链恒定区之一，例如γ(大约330个氨基酸)。
“抗体”包括任何同型体的抗体或免疫球蛋白，或保持与抗原特异结合的抗体片段，包括但不限于Fab，Fv，scFv和Fd片段、嵌合抗体、人源化抗体、单链抗体以及包含抗体的抗原结合部分和非抗体蛋白质的融合蛋白质。抗体可以被标记和检测，例如，可以通过放射性同位素、能产生可检测物的酶、荧光蛋白质、生物素等等进行标记并被检测。抗体还可以结合于固相载体，包括但不限于聚苯乙烯平板或珠粒等等。
“人源化抗体”是指一种抗体，其包含来源于非人源抗体的CDR区、并且该抗体分子的其他部分来源于一种(或几种)人抗体。而且，为了保留结合亲和力，可以修饰骨架(称为FR)区段的一些残基。
所述“纳米抗体”系指在羊驼外周血液中存在一种天然缺失轻链的抗体，该抗体只包含一个重链可变区(VHH)和两个常规的CH2与CH3区，但却不像人工改造的单链抗体片段(scFv)那样容易相互沾粘，甚至聚集成块。更重要的是单独克隆并表达出来的VHH结构具有与原重链抗体相当的结构稳定性以及与抗原的结合活性，是已知的可结合目标抗原的最小单位。VHH晶体为2.5nm，长4nm，分子量只有15KD，因此也被称作纳米抗体(Nanobody，Nb)。VHH可溶性极高，不易聚集，能耐高温、强酸、强碱等致变性条件，适合于原核表达和各种真核表达系统，广泛用于开发治疗性抗体药物、诊断试剂、亲和纯化基质和科学研究等领域。纳米抗体诸多方面均优于传统抗体。基于羊驼重链抗体的VHH单域抗体的特殊结构，兼具了传统抗体与小分子药物的优势，几乎完美克服了传统抗体的开发周期长，稳定性较低，保存条件苛刻等缺陷，逐渐成为新一代治疗性生物医药与临床诊断试剂中的新兴力量。相比于常规抗体，纳米抗体的优势有：1.分子量小，可穿透血脑屏障；2.原核或真核系统中高表达；3.特异性强，亲和力高；4.对人的免疫原性弱。
所述药物中含有至少一种功能成分，还包括可药用的载体。优选地，所述可药用载体是水、缓冲水溶液、等渗盐溶液如PBS(磷酸盐缓冲液)、葡萄糖、甘露醇、右旋葡萄糖、乳糖、淀粉、硬脂酸镁、纤维素、碳酸镁、0.3％甘油、透明质酸、乙醇或聚亚烷基二醇如聚丙二醇、甘油三酯等。所用可药用载体的类型尤其依赖于根据本发明的组合物是否配制为用于口服、鼻、皮内、皮下、肌内或静脉施用。根据本发明的组合物可包含润湿剂、乳化剂或缓冲液物质作为添加剂。
本文使用的“CDR区”或“CDR”是指免疫球蛋白的重链和轻链的高变区，如Kabat etal.所定义(Kabat et al.，Sequences of proteins of immunological interest，5thEd.，U.S.Department of Health and Human Services，NIH，1991，以及以后版本)。存在三个重链CDR和三个轻链CDR。根据情况，本文所用术语CDR或CDRs是为了指示这些区域之一、或者这些区域的几个或者甚至全部，所述区域包含通过抗体对抗原或其识别表位的亲和力而负责结合的大部分氨基酸残基。
本文使用的“FR区”或“FR”是指骨架区，在免疫球蛋白的H和L链的近N端约有110个氨基酸序列的变化很大，其他部分的氨基酸序列相对恒定，据此可将轻链和重链区分为可变区(V)和恒定区(C)。VH和VL。各有3个区域的氨基酸组成和排列顺序高度变化，称为高变区(HVR)或互补决定区(CDR)，分别为CDRl、CDR2和CDR3。CDR以外区域的氨基酸组成和排列顺序相对不易变化，称为骨架区(FR)。VH和VL，各有113和107个氨基酸残基，组成4个FR(分别为FRl、FR2、FR3和FR4)和3个CDR(CDR1、CDR2、CDR3)。
本发明提供的纳米抗体及其应用中所用原料及试剂均可由市场购得。
下面结合实施例，进一步阐述本发明：
实施例1动物免疫
将基因工程重组F蛋白与弗氏佐剂等体积混合并乳化均匀，免疫羊驼，每两周免疫一次，共免疫4次，第一次使用弗氏完全佐剂，其余几次使用不完全佐剂。
实施例2免疫动物血清效价检测
以0.05M碳酸盐包被液稀释基因工程重组F蛋白至2μg/ml，每孔100μl，4℃过夜；次日弃包被液，洗涤3次，每次5min；加入3％BSA封闭液，每孔200μl，37℃放置2h，洗涤后真空干燥备用。每孔加入100μl以样本稀释液稀释的待检血清，37℃孵育1h，洗板5次，每次5min；再加入HRP标记的二抗，37℃45min，洗板5次，每次5min；加入TMB底物每孔100μl，37℃15min。于各反应孔中加入2M硫酸50μl终止反应。结果如表1所示。
表1.免疫动物血清效价ELISA检测结果
实施例3 RSV纳米抗体文库的构建
取适量淋巴细胞进行RNA提取。以提取的RNA为模板进行反转录。以cDNA为模板，单域特异性引物进行两轮PCR扩增，1.2％琼脂糖凝胶鉴定。第一轮回收600bp左右的抗体基因片段，并将小于400bp单域抗体基因片段进行回收(图1)。用限制性内切酶对片段及载体进行酶切过夜，载体回收4000bp左右片段(图2)。用T4连接酶将回收片段与载体16℃连接过夜。TG1电转化，取电转后总菌液中的30μl稀释1000倍涂布150μl于15cm平板，培养过夜，计数。库容＝单克隆×稀释倍数×总体积÷涂板体积。
单菌落个数为85个，总体积75ml，根据稀释倍数计算的库容量为4.1×107cfu。
将达到库容量的平板上的菌刮下，加入70％甘油，使菌液终浓度在15％的甘油内，－80℃冻存。随机挑选单菌落进行阳性率测定(图3)。随机挑选单菌落进行测序，查看序列重复率。
单域抗体PCR产物1.5％凝胶鉴定结果如(图1)，回收1#约600bp和2#，3#400bp左右条带。
载体双酶切1％凝胶鉴定结果如(图2)，回收4000bp左右条带。
实施例4噬菌体抗体库淘筛
包被呼吸道合胞病毒F蛋白，对噬菌体库进行三轮“吸附-洗脱-扩增”的亲和筛选。由于该抗原包含一段无关区域，故采用无关蛋白先进行噬菌体库吸附后再与F蛋白结合，减少非特异抗体的吸附。
表2.噬菌体抗体库淘筛回收率
第二轮筛选后扩增噬菌体抗体库进行无关蛋白吸附(百克PA90)
表3.噬菌体抗体库进行无关蛋白吸附结果
以呼吸道合胞病毒F蛋白为目的抗原进行亲和筛选，第二轮筛选回收率较第一轮提高了93倍，第三轮较第二轮提高了0.451倍，文库到达富集目的。由于该抗原存在一段无关蛋白区域，故又将第二轮扩增后的噬菌体抗体库先进行无关蛋白吸附后，再与F蛋白结合，洗脱，扩增(进行两轮筛选)。均有不同程度的富集。
实施例5构建原核表达库
使用高保真酶进行PCR反应，目的基因400bp左右，纯化回收。双酶切PCR产物、载体pSJF2，纯化回收。按照连接酶的说明书进行，所加入量分子比vector:PCR＝1:3。TG1电转化，取100ul/板涂布LB/Amp平板，32℃培养过夜。菌落PCR鉴定转化效率。随机挑取96个单克隆在96孔板培养并进行ELISA阳性克隆筛选。阳性克隆培养保存，送样测序。根据测序结果CDR1，CDR2，CDR3的不同分型归类。分型后选择需表达纯化的单克隆。
实施例6 RSV纳米抗体的表达与分离纯化
RSV纳米抗体的表达
将纳米抗体的基因序列插入表达载体pET23a，并转入大肠杆菌BL21细胞；用LB培养基。在温度37℃条件下培养。在菌体浓度达到OD6001-1.5时，加入浓度为1M的IPTG进行诱导；继续培养，3-4h后去上行收集菌体。用裂解缓冲液，重悬菌体，超声裂解细胞。收集上清液以及沉淀。用15％的SDS-PAGE电泳检测纳米抗体。
RSV纳米抗体的纯化
采用Ni-NTA亲和层析柱纯化蛋白：
(1)层析柱用上样缓冲液(20mM PBS，50mM咪唑，500mM NaCl)
平衡缓冲液后，加入离心收集的上清液；
(2)先用清洗缓冲液(20mM PBS，100mM咪唑，500mM NaCl)清
洗去除杂蛋白，再用洗脱缓冲液(20mM PBS，500mM咪唑，500mM NaCl)洗脱并收集洗脱液；
(3)纯化后的抗体用15％的SDS-PAGE电泳检测蛋白的纯化情况。如图4所示，抗体分子量在15～20KD之间。
实施例7 RSV纳米抗体的结合活性
将RSV基因工程重组F蛋白100倍稀释后包被96孔ELISA板，4℃过夜，100ul/孔；封闭液37℃封闭2h。将纳米抗体按3倍系列稀释，37℃孵育1h，洗涤3遍；用HRP标记的抗His标签抗体作为二抗，37℃孵育1h，洗涤5遍；加入底物显色液100μl/孔；37℃避光显色15min；用2M硫酸终止反应；用450nm波长进行比色检测，分析结果。如图5或表4所示，检测结果的OD值与抗体浓度呈现明显的剂量依赖效应。
表4.抗体与F蛋白结合活性检测
实施例8 RSV纳米抗体的中和活性测定
(1)加抗体，取一块96孔板横向使用，对待检抗体进行3倍系列稀释，每孔加入50μl样品稀释液。每孔加入相应样品25μl，排枪由第一行混匀后吸25μl至第二行混匀，依次混匀稀释至最后一行弃去25μl。
(2)稀释RSV病毒A2株(确定病毒2×104PFU/ml)：稀释后向96孔板加入50μl/孔，细胞阴性不加病毒。
(3)将细胞培养板轻拍混匀，放至37℃，5％CO2中孵育2h。
(4)用消化液消化细胞，制备细胞悬液浓度为1-2×105个/ml，每孔分别加入0.1mL细胞悬液，混匀，放入37℃，5％CO2孵箱中孵育培养。
(5)使用倒置显微镜每天观察CPE，以抑制50％细胞病变的血清最高稀释度的倒数为终点效价，培养6d后判定结果。
(6)染色法：细胞观察后也可以进行染色法判断，弃去上清液，加入结晶紫染色固定液100μl/孔，染色24h。
(7)去除染色液，用流水冲洗培养板，放置晾干。
(8)测定中和抗体滴度，中和抗体滴度定义为有50％以上完整HEP2细胞的最后一个抗体稀释度。
如图6与表5所示，4-BF-5-hFC，12-Fh-46-hFC和5-Fb-34的中和活性分别为3.6U/mg，2.8U/mg和3.4U/mg。
表5.单域抗体中和活性检测
| 抗体类别 | Positive | 4-BF-42 | 12-Fh-65 | 5-Fb-34 | Negative |
| 中和活性 | 850 | 3.6 | 2.8 | 3.4 | 0.03 |
实施例9制备RSV病毒检测制剂的应用(ELISA)
(1)将RSV基因工程重组F蛋白50-100ug/剂与弗氏佐剂乳化均匀免疫新西兰大白兔，第一次使用弗氏完全佐剂，其余三次使用不完全佐剂；
(2)将获得的F蛋白抗血清300倍稀释后包被96孔ELISA板，4℃过夜，100ul/孔；
(3)封闭液37℃封闭2h。将F蛋白按2倍系列稀释，37℃孵育1h，洗涤3遍；
(4)加入1ug/ml浓度的纳米抗体，37℃孵育1h，洗涤5遍；
(5)加入HRP标记的抗His标签抗体，37℃孵育1h，洗涤5遍；加入底物显色液100μl/孔；
(6)37℃避光显色15min；用2M硫酸终止反应；用450nm波长进行比色检测，分析结果。如表6所示，检测结果的OD值与F蛋白抗原结果浓度呈现明显的剂量依赖效应，非常适合F蛋白抗原浓度检测。
表6.夹心ELISA检测F蛋白结果
| F蛋白稀释倍数 | 4 | 8 | 16 | 32 | 64 | 128 | 256 |
| 4-BF-5OD1 | 2.399 | 1.507 | 0.913 | 0.571 | 0.3 | 0.146 | 0.103 |
| 4-BF-5OD2 | 2.177 | 1.584 | 0.943 | 0.578 | 0.301 | 0.164 | 0.072 |
| 12-Fh-46OD1 | 1.563 | 1.101 | 0.690 | 0.357 | 0.147 | 0.105 | 0.052 |
| 12-Fh-46OD2 | 1.657 | 1.032 | 0.713 | 0.324 | 0.129 | 0.098 | 0.035 |
| 5-Fb-34OD1 | 2.129 | 1.423 | 0.834 | 0.465 | 0.286 | 0.115 | 0.062 |
| 5-Fb-34OD2 | 1.983 | 1.457 | 0.797 | 0.435 | 0.253 | 0.107 | 0.049 |
实施例10抗体衍生物的应用
单域抗体的分子量较小通过AAA作为Linker将VHH连接形成同源二聚体，参照实施例6 RSV抗体的表达与分离纯化，制备4-BF-5的单体(Monomer)与二聚体(Dimer)；同时制备12-Fh-46的单体(Monomer)与二聚体(Dimer)；制备5-Fb-34的单体(Monomer)与二聚体(Dimer)。
人源化的单域抗体采用瞬时转染的方式表达制备
1、4-BF-5-hFC，12-Fh-46-hFC和5-Fb-34质粒制备
1)设计、优化并合成4-BF-5-hFC，12-Fh-46-hFC和5-Fb-34DNA序列；
2)将完整序列亚克隆到pcDNA3.4载体中；
3)转染级质粒制备用于表达Expi293F细胞。
2、细胞培养和瞬时转染：
1)Expi293F细胞在无血清Expi293中生长表达介质(Thermo FisherScientific)。
2)细胞保存在37℃的Erlenmeyer烧瓶中，8％的CO2放在震摇培养箱上。
3)在转染前一天，将细胞以适当的密度接种于培养皿中。
4)在转染当天，DNA和ExpiFectamineTM293试剂以最佳比例混合，然后加入细胞准备转染的烧瓶中。
5)目的抗体重组质粒瞬时共转染悬液中Expi293F细胞培养。
6)第6天收集的细胞培养上清用于纯化。
3、4-BF-5-hFC，12-Fh-46-hFC和5-Fb-34纯化
1)细胞培养液离心后过滤。
2)过滤后的细胞培养上清以适当的流速装载到亲和纯化(Monofinity A Resin)柱上。
3)用适当的缓冲液洗涤和洗脱后，将洗脱的部分混合并交换缓冲液最终配方缓冲液。
将所获得的单域抗体二聚体与人源化抗体采用实施例8 RSV抗体的中和活性测定，检测结果如图7与表7所示，表明单域抗体通过二聚化或人源化后抗体的中和活性都有显著提升，对RSV病毒具有良好的中和作用。
表7.单域抗体人源化和二聚体检测结果
实施例11抗体及其衍生物动物水平中和活性检测
(1)病毒悬液制备:RSV病毒A2株接种于Hep-2细胞上，按常规培养，在细胞融合病变最明显时，用力振荡细胞瓶，使细胞从瓶壁脱落，反复冻融3次，4℃离心(800×g，10min)，去除细胞散片。收集病毒悬液，进行病毒滴定，用于动物接种。
(2)动物接种过程:选用鼻腔接种法。豚鼠(每组3只)麻醉完全后，鼻腔内缓慢滴入50TCID50病毒与50个活性单位的RSV抗体悬液0.3ml；阴性对照组动物滴入PBS液0.3ml；阳性对照组缓慢滴入50TCID50病毒悬液0.3ml。每天1次，连滴3天。
(3)肺组织标本处理:采用急性失血法处死豚鼠。无菌条件下，取出部分肺组织置于灭菌Hank's液中，用于病毒分离。
(4)肺组织病毒分离:无菌条件下，剪碎新鲜的肺组织标本，研磨后接种到Hep-2细胞瓶中，观察细胞病变，待细胞融合病变时，收取标本，用免疫荧光法鉴定RSV。
免疫荧光法:含有病毒抗原的Hep-2细胞制成抗原片，冷丙酮固定20分钟，取出晾干。每孔加入1滴RSV/FITC抗体试剂，37℃温盒孵育30分钟，晾干后用基质液封片，移至荧光显微镜下观察。
检测结果如表8和图8所示，豚鼠体内中和活性检测结果表明，单域抗体及其衍生物在动物水平表现出良好的中和活性。
表8.单域抗体及其衍生物豚鼠体内中和活性检测结果
以上所述仅是本发明的优选实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 长春百克生物科技股份公司
<120> 纳米抗体及其应用
<130> MP2018748
<160> 19
<170> SIPOSequenceListing 1.0
<210> 1
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ser Ile Phe Pro Phe Asn Asn Met Gly
1 5
<210> 2
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Ala Thr Thr His Gly Val Ile Asn Ile
1 5
<210> 3
<211> 9
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Ala Thr Thr His Gly Val Ile Asn Leu
1 5
<210> 4
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Tyr Gly Lys Phe Pro Thr Gly Gly Tyr Met Thr Asp Tyr
1 5 10
<210> 5
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Tyr Gly Lys Phe Pro Val Gly Gly Tyr Met Thr Asp Tyr
1 5 10
<210> 6
<211> 13
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Tyr Gly Lys Phe Pro Leu Gly Gly Tyr Met Thr Asp Tyr
1 5 10
<210> 7
<211> 26
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly
20 25
<210> 8
<211> 15
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val Ala Thr
1 5 10 15
<210> 9
<211> 36
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys
1 5 10 15
Asn Thr Val Asn Leu Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly
20 25 30
Val Tyr Tyr Cys
35
<210> 10
<211> 22
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
Trp Gly Gln Gly Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile
1 5 10 15
Ser Glu Glu Asp Leu Asn
20
<210> 11
<211> 130
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Pro Phe Asn
20 25 30
Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Thr Ala Thr Thr His Gly Val Ile Asn Ile Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu
65 70 75 80
Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly Val Tyr Tyr Cys Tyr
85 90 95
Gly Lys Phe Pro Thr Gly Gly Tyr Met Thr Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp
115 120 125
Leu Asn
130
<210> 12
<211> 130
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Pro Phe Asn
20 25 30
Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Thr Ala Thr Thr His Gly Val Ile Asn Ile Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu
65 70 75 80
Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly Val Tyr Tyr Cys Tyr
85 90 95
Gly Lys Phe Pro Val Gly Gly Tyr Met Thr Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp
115 120 125
Leu Asn
130
<210> 13
<211> 130
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Pro Phe Asn
20 25 30
Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Thr Ala Thr Thr His Gly Val Ile Asn Leu Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu
65 70 75 80
Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly Val Tyr Tyr Cys Tyr
85 90 95
Gly Lys Phe Pro Leu Gly Gly Tyr Met Thr Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp
115 120 125
Leu Asn
130
<210> 14
<211> 264
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Pro Phe Asn
20 25 30
Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Thr Ala Thr Thr His Gly Val Ile Asn Ile Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu
65 70 75 80
Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly Val Tyr Tyr Cys Tyr
85 90 95
Gly Lys Phe Pro Thr Gly Gly Tyr Met Thr Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp
115 120 125
Leu Asn Ala Ala Ala Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu
130 135 140
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser
145 150 155 160
Ile Phe Pro Phe Asn Asn Met Gly Thr Trp Tyr Arg Gln Ala Pro Gly
165 170 175
Lys Gln Arg Glu Leu Val Ala Thr Ala Thr Thr His Gly Val Ile Asn
180 185 190
Ile Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
195 200 205
Lys Asn Thr Val Asn Leu Gln Met Asn Asn Leu Asn Pro Glu Asp Thr
210 215 220
Gly Val Tyr Tyr Cys Tyr Gly Lys Phe Pro Thr Gly Gly Tyr Met Thr
225 230 235 240
Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Gly Ser Glu Gln Lys
245 250 255
Leu Ile Ser Glu Glu Asp Leu Asn
260
<210> 15
<211> 264
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 15
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Pro Phe Asn
20 25 30
Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Thr Ala Thr Thr His Gly Val Ile Asn Ile Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu
65 70 75 80
Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly Val Tyr Tyr Cys Tyr
85 90 95
Gly Lys Phe Pro Val Gly Gly Tyr Met Thr Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp
115 120 125
Leu Asn Ala Ala Ala Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu
130 135 140
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser
145 150 155 160
Ile Phe Pro Phe Asn Asn Met Gly Thr Trp Tyr Arg Gln Ala Pro Gly
165 170 175
Lys Gln Arg Glu Leu Val Ala Thr Ala Thr Thr His Gly Val Ile Asn
180 185 190
Ile Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
195 200 205
Lys Asn Thr Val Asn Leu Gln Met Asn Asn Leu Asn Pro Glu Asp Thr
210 215 220
Gly Val Tyr Tyr Cys Tyr Gly Lys Phe Pro Val Gly Gly Tyr Met Thr
225 230 235 240
Asp Tyr Trp Gly Gln Gly Thr Gln Val Thr Val Gly Ser Glu Gln Lys
245 250 255
Leu Ile Ser Glu Glu Asp Leu Asn
260
<210> 16
<211> 228
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 16
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Pro Phe Asn
20 25 30
Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Thr Ala Thr Thr His Gly Val Ile Asn Leu Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu
65 70 75 80
Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly Val Tyr Tyr Cys Tyr
85 90 95
Gly Lys Phe Pro Leu Gly Gly Tyr Met Thr Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp
115 120 125
Leu Asn Ala Ala Ala Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu
130 135 140
Val Gln Pro Gly Gly Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser
145 150 155 160
Ile Phe Pro Phe Asn Asn Met Gly Thr Trp Tyr Arg Gln Ala Pro Gly
165 170 175
Lys Gln Arg Glu Leu Val Ala Thr Ala Thr Thr His Gly Val Ile Asn
180 185 190
Leu Ala Asp Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala
195 200 205
Lys Asn Thr Val Asn Leu Gln Met Asn Asn Leu Asn Pro Glu Asp Thr
210 215 220
Gly Val Tyr Tyr
225
<210> 17
<211> 357
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Pro Phe Asn
20 25 30
Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Thr Ala Thr Thr His Gly Val Ile Asn Ile Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu
65 70 75 80
Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly Val Tyr Tyr Cys Tyr
85 90 95
Gly Lys Phe Pro Thr Gly Gly Tyr Met Thr Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp
115 120 125
Leu Asn Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
130 135 140
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
145 150 155 160
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
165 170 175
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
180 185 190
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
195 200 205
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
210 215 220
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
225 230 235 240
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
245 250 255
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
260 265 270
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
275 280 285
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
290 295 300
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
305 310 315 320
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
325 330 335
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
340 345 350
Leu Ser Pro Gly Lys
355
<210> 18
<211> 357
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 18
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Pro Phe Asn
20 25 30
Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Thr Ala Thr Thr His Gly Val Ile Asn Ile Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu
65 70 75 80
Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly Val Tyr Tyr Cys Tyr
85 90 95
Gly Lys Phe Pro Val Gly Gly Tyr Met Thr Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp
115 120 125
Leu Asn Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
130 135 140
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
145 150 155 160
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
165 170 175
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
180 185 190
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
195 200 205
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
210 215 220
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
225 230 235 240
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
245 250 255
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
260 265 270
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
275 280 285
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
290 295 300
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
305 310 315 320
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
325 330 335
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
340 345 350
Leu Ser Pro Gly Lys
355
<210> 19
<211> 357
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 19
Glu Val Gln Leu Gln Ala Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Ser Ile Phe Pro Phe Asn
20 25 30
Asn Met Gly Trp Tyr Arg Gln Ala Pro Gly Lys Gln Arg Glu Leu Val
35 40 45
Ala Thr Ala Thr Thr His Gly Val Ile Asn Leu Ala Asp Ser Val Lys
50 55 60
Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Val Asn Leu
65 70 75 80
Gln Met Asn Asn Leu Asn Pro Glu Asp Thr Gly Val Tyr Tyr Cys Tyr
85 90 95
Gly Lys Phe Pro Leu Gly Gly Tyr Met Thr Asp Tyr Trp Gly Gln Gly
100 105 110
Thr Gln Val Thr Val Gly Ser Glu Gln Lys Leu Ile Ser Glu Glu Asp
115 120 125
Leu Asn Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu
130 135 140
Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr
145 150 155 160
Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val
165 170 175
Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val
180 185 190
Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser
195 200 205
Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu
210 215 220
Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala
225 230 235 240
Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro
245 250 255
Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln
260 265 270
Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala
275 280 285
Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr
290 295 300
Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu
305 310 315 320
Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser
325 330 335
Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser
340 345 350
Leu Ser Pro Gly Lys
355
Claims (17)
1.纳米抗体，其特征在于，所述纳米抗体包括三个互补决定区CDR1、CDR2、CDR3；其中
(I)、所述纳米抗体的互补决定区CDR1具有如SEQ ID No.1所示的氨基酸序列；和/或
所述纳米抗体的互补决定区CDR2具有如SEQ ID No.2或3所示的氨基酸序列；和/或
所述纳米抗体的互补决定区CDR3具有如SEQ ID No.4～6任一项所示的氨基酸序列；
或(II)、如(I)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(I)所述氨基酸序列功能相同的氨基酸序列；
或(III)、与(I)或(II)所述氨基酸序列具有80％以上同一性的氨基酸序列。
2.如权利要求1所述的纳米抗体，其特征在于，所述纳米抗体还包括四个恒定区FR1、FR2、FR3、FR4，其中，
(IV)、所述纳米抗体的恒定区FR1具有如SEQ ID No.7所示的氨基酸序列；和/或
所述纳米抗体的恒定区FR2具有如SEQ ID No.8所示的氨基酸序列；和/或
所述纳米抗体的恒定区FR3具有如SEQ ID No.9所示的氨基酸序列；和/或
所述纳米抗体的恒定区FR4具有如SEQ ID No.10所示的氨基酸序列；
或(V)、如(IV)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(IV)所述氨基酸序列功能相同的氨基酸序列；
或(VI)、与(IV)或(V)所述氨基酸序列具有80％以上同一性的氨基酸序列。
3.如权利要求1所述的纳米抗体，其特征在于，
(VII)、所述纳米抗体具有如SEQ ID No.11～13中任一项所示的氨基酸序列；
或
(VIII)、如(VII)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(VII)所述氨基酸序列功能相同的氨基酸序列；
或
(IX)、与(VII)或(VIII)所述氨基酸序列具有80％以上同一性的氨基酸序列。
4.如权利要求1至3任一项所述的纳米抗体的二聚体，其特征在于，
(X)、所述纳米抗体的二聚体具有如SEQ ID No.14～16中任一项所示的氨基酸序列；
或
(XI)、如(X)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(X)所述氨基酸序列功能相同的氨基酸序列；
或
(XII)、与(X)或(XI)所述氨基酸序列具有80％以上同一性的氨基酸序列。
5.人源化RSV纳米抗体，其特征在于，
(XIII)、所述人源化RSV纳米抗体具有如SEQ ID No.17～19中任一项所示的氨基酸序列；
或
(XIV)、如(XIII)所述氨基酸序列经取代、缺失或添加一个或多个氨基酸获得的氨基酸序列，且与(XIII)所述氨基酸序列功能相同的氨基酸序列；
或
(XV)、与(XIII)或(XIV)所述氨基酸序列具有80％以上同一性的氨基酸序列。
6.编码如权利要求1～3任一项所述的纳米抗体、编码如权利要求5所述的纳米抗体的二聚体或编码如权利要求5所述的人源化RSV纳米抗体的核苷酸。
7.一种表达载体，包括如权利要求6所述的核苷酸。
8.转化或转染如权利要求7所述的表达载体的宿主细胞。
9.结合物，其特征在于，包含经化学标记或生物标记的如权利要求1～3任一项所述的纳米抗体、如权利要求4所述的纳米抗体的二聚体或如权利要求5所述的人源化RSV纳米抗体。
10.如权利要求1～3任一项所述的纳米抗体、如权利要求4所述的纳米抗体的二聚体或如权利要求5所述的人源化RSV纳米抗体或如权利要求9所述的结合物与固体介质或半固体介质偶联制得的偶联物。
11.如权利要求1～3任一项所述的纳米抗体、如权利要求4所述的纳米抗体的二聚体、如权利要求5所述的人源化RSV纳米抗体、如权利要求9所述的结合物和/或如权利要求10所述的偶联物在制备RSV病毒诊断试剂和/或试剂盒中的应用。
12.如权利要求1～3任一项所述的纳米抗体、如权利要求4所述的纳米抗体的二聚体、如权利要求5所述的人源化RSV纳米抗体、如权利要求9所述的结合物和/或如权利要求10所述的偶联物在制备预防和/或治疗RSV病毒相关疾病的药物中的应用。
13.RSV病毒诊断试剂，其特征在于，包括如权利要求1～3任一项所述的纳米抗体、如权利要求4所述的纳米抗体的二聚体、如权利要求5所述的人源化RSV纳米抗体、如权利要求9所述的结合物和/或如权利要求10所述的偶联物以及可接受的助剂。
14.RSV病毒诊断试剂盒，其特征在于，包括如权利要求1～3任一项所述的纳米抗体、如权利要求4所述的纳米抗体的二聚体、如权利要求5所述的人源化RSV纳米抗体、如权利要求9所述的结合物和/或如权利要求10所述的偶联物以及可接受的助剂和/或载体。
15.疾病的诊断方法，其特征在于，以如权利要求13所述的RSV病毒诊断试剂或如权利要求14所述的RSV病毒诊断试剂盒检测RSV表达，根据表达量判断是否患有疾病。
16.预防和/或治疗RSV病毒相关疾病的药物，其特征在于，包括如权利要求1～3任一项所述的纳米抗体、如权利要求4所述的纳米抗体的二聚体、如权利要求5所述的人源化RSV纳米抗体、如权利要求9所述的结合物和/或如权利要求10所述的偶联物以及可接受的辅料。
17.疾病的预防和/或治疗方法，其特征在于，给予如权利要求16所述的药物。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011125794.6A CN112225805B (zh) | 2020-10-20 | 2020-10-20 | 纳米抗体及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202011125794.6A CN112225805B (zh) | 2020-10-20 | 2020-10-20 | 纳米抗体及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112225805A true CN112225805A (zh) | 2021-01-15 |
| CN112225805B CN112225805B (zh) | 2023-03-21 |
Family
ID=74118123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011125794.6A Active CN112225805B (zh) | 2020-10-20 | 2020-10-20 | 纳米抗体及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112225805B (zh) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101659697A (zh) * | 2009-09-15 | 2010-03-03 | 中国医学科学院医学生物学研究所 | 人呼吸道合胞病毒的裂解方法 |
| CN104628850A (zh) * | 2009-10-06 | 2015-05-20 | 医学免疫有限公司 | Rsv-特异性结合分子 |
| CN111440859A (zh) * | 2020-03-18 | 2020-07-24 | 中国医学科学院病原生物学研究所 | 一种人呼吸道合胞病毒感染的生物标志物及应用 |
-
2020
- 2020-10-20 CN CN202011125794.6A patent/CN112225805B/zh active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101659697A (zh) * | 2009-09-15 | 2010-03-03 | 中国医学科学院医学生物学研究所 | 人呼吸道合胞病毒的裂解方法 |
| CN104628850A (zh) * | 2009-10-06 | 2015-05-20 | 医学免疫有限公司 | Rsv-特异性结合分子 |
| CN111440859A (zh) * | 2020-03-18 | 2020-07-24 | 中国医学科学院病原生物学研究所 | 一种人呼吸道合胞病毒感染的生物标志物及应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN112225805B (zh) | 2023-03-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103483447B (zh) | 抗hpv l1蛋白的广谱单克隆抗体或其抗原结合片段及它们的用途 | |
| CN105669838A (zh) | 来自水痘-带状疱疹病毒gE蛋白的中和表位及针对其的抗体 | |
| WO2016173559A1 (zh) | 抗诺如病毒gi.1型鼠源单克隆抗体的制备和应用 | |
| WO2022179535A1 (zh) | 抗SARS-CoV-2核衣壳蛋白的单克隆抗体及其制备方法和用途 | |
| CN114702576B (zh) | 抗新型冠状病毒s蛋白受体结合区的单域抗体及其编码基因和应用 | |
| EP1178829A1 (en) | Human monoclonal antibody | |
| CN111205366B (zh) | 抗hpv45l1的单克隆中和抗体及其应用 | |
| CN112225804A (zh) | 纳米抗体及其应用 | |
| CN114685664B (zh) | 抗人b淋巴细胞表面抗原cd20的单域抗体及其应用 | |
| CN112225805B (zh) | 纳米抗体及其应用 | |
| CN112225803B (zh) | 纳米抗体及其应用 | |
| CN109942702A (zh) | 一种人鼠嵌合抗HEV全分子IgG及其应用 | |
| CN111205364B (zh) | 抗hpv31l1的单克隆中和抗体及其应用 | |
| CN112225802A (zh) | 纳米抗体及其应用 | |
| CN112250761A (zh) | 纳米抗体及其应用 | |
| CN112225801A (zh) | 纳米抗体及其应用 | |
| CN112225800A (zh) | 纳米抗体及其应用 | |
| CN116425868A (zh) | 一种抗柯萨奇病毒a10型的单克隆抗体及其制备方法和应用 | |
| CN101198374B (zh) | 具有抗hiv中和活性的抗体或其片段 | |
| WO2022068895A1 (zh) | 抗SARS-CoV-2刺突蛋白膜外区的单克隆抗体及其应用 | |
| CN111116740B (zh) | Hpv33l1的单克隆中和抗体及其应用 | |
| CN111732653B (zh) | Hpv52l1的单克隆中和抗体及其应用 | |
| CN111560067B (zh) | Hpv58l1的单克隆中和抗体及其应用 | |
| CN111662378B (zh) | Hpv18l1的单克隆中和抗体及其应用 | |
| CN111560068B (zh) | Hpv16l1的单克隆中和抗体及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |